Focus: City Therapeutics is a Cambridge-based biotechnology company founded in 2018 specializing in next-generation RNAi therapies for gene therapy indications. With 5,000+ employees and public status, it operates at the scale of a mid-to-large biotech organization advancing precision genetic medicine.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
City Therapeutics offers meaningful early-stage RNAi exposure and growth capital, but job seekers should verify pipeline focus, publication cadence, and hiring trajectory before committing to a company with unclear clinical data quality.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for City Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from City Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
City Therapeutics Advances RNAi Pipeline as CITY-FXI Enters Clinic and Stargardt Program Approaches IND - BioPharm International
City Therapeutics Advances RNAi Pipeline as CITY-FXI Enters Clinic and Stargardt Program Approaches IND BioPharm International
Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering - Pharmaceutical Executive
Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering Pharmaceutical Executive
City banks nearly $100M for next-gen RNAi drugs - BioPharma Dive
City banks nearly $100M for next-gen RNAi drugs BioPharma Dive
City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics - Business Wire
City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics Business Wire
City Therapeutics Presents Preclinical Data on Next-Generation Investigational RNAi Therapy CITY-RBP4 for Treatment of Stargardt Disease at ARVO 2026 Annual Meeting - Business Wire
City Therapeutics Presents Preclinical Data on Next-Generation Investigational RNAi Therapy CITY-RBP4 for Treatment of Stargardt Disease at ARVO 2026 Annual Meeting Business Wire
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Population-Based Modeling to Predict Human PK/PD of TAK-500, an Anti-CCR2 Antibody-Drug Conjugate for First-in-Human Study in Cancer Patients.
Integration of in situ hybridization and scRNA-seq data provides a 2D topographical map of the developing retina across species.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo